Skip Navigation

Annals of Oncology 2007 18(10):1589; doi:10.1093/annonc/mdm473
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Prognostic role of peritumoral vascular invasion in operable breast cancer
 
For breast cancer patients with peritumoral vascular invasion (PVI), treatment choice follows an algorithm similar to that for node-positive disease. Nevertheless, controversies remain about the role of PVI in the risk assessment of patients with operable breast cancer, with several previous studies failing to confirm any prognostic role for vascular invasion. In this issue, Colleoni et al. [1632–1640] report the results of a study that . . . [Full Text of this Article]


   Gemcitabine plus platinum in pancreatic cancer
 

   Disease progression in Hodgkin's lymphoma
 

   Immunotherapy versus DTIC in melanoma
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer
M. Colleoni, N. Rotmensz, P. Maisonneuve, A. Sonzogni, G. Pruneri, C. Casadio, A. Luini, P. Veronesi, M. Intra, V. Galimberti, R. Torrisi, S. Andrighetto, R. Ghisini, A. Goldhirsch, and G. Viale
Ann Oncol 2007 18: 1632-1640. [Abstract] [FREE Full Text]  

Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study
V. Heinemann, R. Labianca, A. Hinke, and C. Louvet
Ann Oncol 2007 18: 1652-1659. [Abstract] [FREE Full Text]  

Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma
D. A. Macdonald, K. Ding, M. K. Gospodarowicz, W. A. Wells, R. G. Pearcey, J. M. Connors, J. N. Winter, S. J. Horning, M. S. Djurfeldt, L. E. Shepherd, and R. M. Meyer
Ann Oncol 2007 18: 1680-1684. [Abstract] [FREE Full Text]  

Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma
M. Middleton, A. Hauschild, D. Thomson, R. Anderson, S. Burdette-Radoux, K. Gehlsen, K. Hellstrand, and P. Naredi
Ann Oncol 2007 18: 1691-1697. [Abstract] [FREE Full Text]